CD Biosynsis offers high-precision Sf9 Cells Gene Knock-in Services, enabling the stable, accurate integration of large expression cassettes and therapeutic genes into the host genome. Sf9 cells (derived from Spodoptera frugiperda) are the foundational host for the Baculovirus Expression Vector System (BEVS). Gene knock-in is a critical step in strain engineering, utilized to achieve stable, constitutive expression by inserting the gene of interest (GOI) or an entire metabolic pathway at defined genomic loci. Leveraging the precision of CRISPR-Cas9 to induce double-strand breaks (DSBs), our services rely on the cell's Homology-Directed Repair (HDR) pathway to integrate the desired DNA fragment accurately. We provide end-to-end solutions, from multi-gene cassette design to final clone screening, accelerating the development of superior Sf9 cell lines with enhanced stability, improved product quality (e.g., humanized glycosylation), and reliable expression independent of the viral vector.
Get a QuoteGene knock-in in Sf9 cells is designed to move beyond the transient, high-titer, but structurally limiting expression provided by the BEVS system itself. Our strategy utilizes CRISPR-Cas9 to precisely cut a pre-selected genomic safe harbor locus or a site targeted for pathway replacement. The cell then uses the provided large DNA donor template via the Homology-Directed Repair (HDR) pathway to integrate the gene cassette (e.g., human glycosylation enzymes, chaperones) accurately. This ensures stable, constitutive expression of the host modification, providing a highly optimized chassis ready for BEVS production. This is paramount for achieving tailored product quality attributes (CQAs), such as humanized N-glycans.
Safe Harbor Targeting
Identification of optimal genomic safe harbor loci for integration, ensuring stable, constitutive expression of the modified trait (e.g., human glycosylation enzymes) without disrupting essential host functions.
Large Donor Template Design
Design of large DNA repair templates (up to 10kb) with optimal promoters (e.g., OpIE2) and selection markers, flanked by long homology arms (HDR templates) to maximize the integration rate via the Sf9 HDR pathway.
Multi-Enzyme Pathway Insertion
Strategy for the single-step integration of multiple expression units (e.g., an entire human glycosylation pathway) to ensure balanced and functional expression of all necessary components.
RNP Delivery System
Preference for Ribonucleoprotein (RNP) delivery for transient, high-efficiency, and low off-target activity, maximizing editing speed and minimizing Cas9 toxicity in Sf9 cells.
Optimized NLS-Cas9
Use of Cas9 equipped with a Nuclear Localization Signal (NLS) tag to ensure efficient transport of the editing complex into the Sf9 nucleus for genomic access.
Marker Selection System
Integration of selection markers (e.g., Puromycin, Blasticidin) into the donor cassette to enrich for cells that have successfully undergone the HDR-mediated knock-in event.
Humanized Glycosylation Pathway
Accurate knock-in of human glycosylation enzymes (e.g., GNT-I, $\beta$-galactosyltransferase) into a glycan-deficient chassis to produce therapeutic proteins with human-like N-glycans.
Enhanced Folding Chaperones
Insertion of highly expressed genes for folding catalysts (e.g., human PDI, BiP) to significantly increase the host's capacity to process complex, disulfide-bonded proteins.
Stable Protein Production
Targeted integration of a gene of interest (GOI) under a strong constitutive promoter for stable expression, useful for producing internal standards or non-BEVS protein production.
A systematic process for achieving precise integration and stable cell line isolation.
1. Rational Design & RNP Preparation
2. Transfection & HDR Integration
3. Clone Isolation & Screening
4. Clone Verification & Delivery
Identify the genomic integration site (safe harbor or target locus). Design gRNA(s) for the Cas9 cut site.
Prepare the Cas9 enzyme/gRNA Ribonucleoprotein (RNP) complex for transient delivery.
Synthesize the large DNA donor template with selection markers and optimal homology arms for Sf9 HDR.
Cotransfect the RNP complex and the large DNA donor into the Sf9 host cell line.
Culture cells to allow the Homology-Directed Repair (HDR) pathway to integrate the donor precisely.
Apply antibiotic selection to enrich for stable integration events.
Genotype verification via junction PCR and definitive sequencing of the integration site to confirm precise HDR.
Phenotypic validation of the final clone for stable expression and functionality (e.g., successful PTMs) over multiple passages.
Delivery of the verified Sf9 master cell bank (MCB) and comprehensive documentation.
Stable Host Chassis Creation
CRISPR-guided HDR integration ensures permanent, constitutive expression of host modifications (e.g., human PTM enzymes), providing a stable foundation for transient BEVS protein production.
Integrated Human Glycosylation
Accurate knock-in of complex mammalian biosynthetic pathways (e.g., N-glycan processing) to resolve the major quality limitation of insect cell systems.
Large Fragment Integration
Optimization for Sf9 cells allows the precise insertion of large DNA expression cassettes (up to 10kb or more) in a single step via the HDR pathway.
High Precision HDR
Optimization of RNP delivery and donor template design maximizes the rate of accurate Homology-Directed Repair, minimizing random integration and undesirable indels.
1. Why is stable genomic knock-in necessary in a transient system like BEVS?
The BEVS is transient for the product gene. Knock-in is used to stably modify the host machinery (e.g., insert human glycosylation enzymes or chaperones). These modified traits are permanent, ensuring the host is optimized for any subsequent BEVS protein production.
2. What is the role of the HDR pathway in Sf9 cells?
The Homology-Directed Repair (HDR) pathway is crucial for Gene Knock-in (KI). It uses the provided donor DNA (flanked by homology arms) as a template to precisely repair the Cas9 cut, allowing for accurate integration of the new gene cassette.
3. Can you integrate entire human biosynthetic pathways in one step?
Yes. Our optimization allows for the precise integration of large DNA cassettes (up to 10kb or more), enabling the stable insertion of multi-enzyme pathways, often linked by internal ribosome entry sites (IRES) or self-cleaving peptides (P2A), in a single KI step.
4. How do you ensure the stable expression of the inserted gene?
The gene cassette is integrated into a verified genomic safe harbor locus via CRISPR/HDR. This ensures the cassette is placed in a transcriptionally active region, guaranteeing high, consistent, and stable expression of the modified trait (e.g., human PTM) over many passages.
5. How is the knock-in verified at the genomic level?
Verification is comprehensive: using junction PCR to confirm successful integration at both the 5' and 3' ends of the targeted locus, followed by Sanger sequencing to confirm the integrity and sequence of the integrated gene cassette.
6. What delivery methods are used for the Cas9/donor DNA?
We typically use optimized electroporation or lipofection to co-deliver the Cas9 RNP complex and the large linear DNA donor template into the Sf9 cells for maximal HDR efficiency.
7. What is the role of the homology arms on the donor template?
Homology arms are DNA sequences that match the genomic sequence flanking the Cas9 cut site. They guide the cell's HDR machinery to accurately integrate the new gene cassette at the specific target locus.
8. What input is required to start a gene knock-in project?
We require the specific Sf9 host cell line, the target genomic safe harbor locus (if known), and the full sequence of the expression cassette to be integrated (including the gene of interest, promoter, and selection marker).
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.